Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: A multicenter, randomized, double-blind, phase III study in North America

Head and Neck

Volumn 25, Issue 9, 2003, Pages 717-731

  Castro, Dan J ^a   Sridhar, Kasi S ^b   Garewal, Harinder S ^c   Mills, Glenn M ^d   Wenig, Barry L ^e   Dunphy II, Frank R ^f,i   Costantino, Peter D ^g,j   Leavitt, Richard D ^h,k   Stewart, Morgan E ^h,l   Orenberg, Elaine K ^h,m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Matrix Pharmaceutical Inc   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^k PharmaPacific Inc   (United States)

^l Applied Molecular Evolution   (United States)

^m Orenberg Anderson Biopharmaceut C   (United States)

more..

Author keywords

Cisplatin; Head and neck cancer; Intratumoral; Phase III trial

Indexed keywords

ADRENALIN; CISPLATIN; MORPHINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EDEMA; ERYTHEMA; FACE EDEMA; FACIAL NERVE PARALYSIS; FEMALE; FEVER; FISTULA; GEL; HEAD AND NECK CANCER; HEADACHE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE; LEG CRAMP; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NECK PAIN; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SKIN NECROSIS; SKIN ULCER; SQUAMOUS CELL CARCINOMA; TACHYCARDIA; TASTE DISORDER; TINNITUS; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; VOMITING; WOUND DRAINAGE;

ADRENERGIC AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOUBLE-BLIND METHOD; EPINEPHRINE; FEMALE; GELS; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORTH AMERICA; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 10744233885     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10261     Document Type: Article

References (60)

1. Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 2000;27(suppl 8): 25-33.
2. Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine, 4th ed. Baltimore, MD: Williams & Wilkins; 1997. p 1645-1710.
3. Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 2000;27(suppl 8):13-24.
4. Eisbruch A, Dawson L. Re-irradiation of head and neck tumors - benefits and toxicities. Hematol Oncol Clin North Am 1999;13:825-836.
5. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-955.
6. Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, Kudla-Hatch V. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987;19:155-158.
7. Havlin KA, Kuhn JG, Myers JW, et al. High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study. Cancer 1989;63:423-427.
8. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
9. Galmarini FC, Galmarini CM, Sarchi MI, Abulafia J, Galmarini D. Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer. Microcirculation 2000;7:405-410.
10. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
11. Robbins KT, Storniolo AM, Kerber C, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 1994;12: 2113-2120.
12. Donegan WL, Harris P. Regional chemotherapy with combined drugs in cancer of the head and neck. Cancer 1976; 38:1479-1483.
13. Frustaci S, Barzan L, Tumolo S, et al. Intra-arterial continuous infusion of cis-diamminedichloroplatinum in untreated head and neck cancer patients. Cancer 1986;57: 1118-1123.
14. Freckman HA. Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy. Am J Surg 1972;124:501-509.
15. Litwin MS, Ryan RF, Reed RJ, Krementz ET. Topical chemotherapy of cutaneous malignancy of the head and neck. South Med J 1969;62:556-558.
16. Zhong PQ, Zhi FX, Li R, Xue JL, Shu GY. Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:139-144.
17. 57Cobleomycin in mice after intravenous, subcutaneous and intratumoral injection. Cancer 1979;44:1194-1200.
18. Merlano M, Esposito M, Fulco RA, Benasso M, Rosso R. Topical administration of cisplatin in far-advanced squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol 1986;22:119-120.
19. Shikani AH, Eisele DW, Domb AJ. Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1994;120: 1242-1247.
20. Musiani P, De Campora E, Valitutti S, et al. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Response Mod 1989; 8:571-578.
21. Mattijssen V, De Mulder PH, Schornagel JH, et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother 1991;10:63-68.
22. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONXY-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-298.
23. Begg AC, Bartelink H, Stewart FA, Brown DM, Luck EE. Improvement of differential toxicity between tumor and normal tissues using intratumoral injection with or without a slow-drug-release matrix system. NCI Monogr 1988; 6:133-136.
24. Yu NY, Conley FK, Luck EE, Brown DM. Response of murine tumors to matrix-associated cisplatin intratumoral implants. NCI Monogr 1988;6:137-140.
25. Robbins KT, Hoffman RM. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. I. Histoculture experiments. Laryngoscope 1996; 106:32-36.
26. Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Laryngoscope 1996;106:37-42.
27. Andrews PA, Murphy MP, Howell SB. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol 1989;25:619-625.
28. Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 1990;2:93-100.
29. Teicher BA, Holden SA, Kelley MJ, et al. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 1987;47: 388-393.
30. Von Hoff DD, Clark GM, Weiss GR, et al. Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986;4:1827-1834.
31. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: DeVita V, Hellman S, Rosenburg SJB, editors. Important advances in oncology. Philadelphia: Lippincott-Raven; 1998. p 121-141.
32. Clayman GL, Dreiling LK. Injectable modalities as local and regional strategies for head and neck cancer. Hematol Oncol Clin North Am 1999;13:787-810.
33. Yu NY, Patawaran MB, Chen JY, Orenberg EK, Brown DM, Luck EE. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo. Cancer J Sci Am 1995;1:215-221.
34. Burris HA 3rd, Vogel CL, Castro D, et al. Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 1998;118:496-503.
35. Kempf W, Dummer R, Schmid MH, Fritz T, Wüthrich B, Burg G. Intralesional cisplatin for the treatment of cutaneous B-cell lymphoma. Arch Dermatol 1998;134: 1343-1345.
36. Harbord M, Bown S, Mishra L, et al. Phase III trials of intratumoral cisplatin/epinephrine injectable gel for treatment of advanced solid tumors. Proc Am Soc Clin Oncol 1999;18:192.
37. Harbord M, Viens P, Eysselein V, Barr H, Bown SG. Intratumoral injection of cisplatin/epinephrine gel for palliation of dysphagia in patients with advanced esophageal cancer. Gastrointest Endosc 1999;49:206.
38. Johnson PJ, Leung TWT, Vogl TJ, et al. Percutaneous administration of cisplatin/epinephrine (CDDP/epi) injectable gel for treatment of intrahepatic lesions of hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2000; 19:263.
39. Hauschild A, Oratz R, Sebastian G, et al. Intratumoral cisplatin/epinephrine injectable gel for treatment of patients with cutaneous and soft tissue metastases of malignant melanoma: an international multicenter study. Presented at Fifth World Conference on Melanoma, Milan & WHO. San Giorgio Maggiore, Italy, Feb 28-March 3, 2001.
40. Mackowiak J, Stewart M, Leavitt R, Burns H 3rd. Validation of the Treatment Goals Questionnaire (TGQ): a new instrument to assess patient benefit following treatment of squamous cell carcinoma of the head and neck (HNSCC) with intratumoral cisplatin/epinephrine injectable (CDDP/epi) gel. Proc Am Soc Clin Oncol 2001;20:232.
41. Werner JA, Castro D, Sridhar KS, et al. A new instrument to assess improvements in quality of life (QoL) attributed to local control of head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol 2000;19:620.
42. Cella DF. F.A.C.T. manual - Functional Assessment of Cancer Therapy (FACT) Scales and Functional Assessment of HIV Infection (FAHI) scale (version 3). Chicago: Rush-Presbyterian-St. Luke's Medical Center; 1994.
43. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
44. Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995;22(suppl 3):73-81.
45. Toxicity criteria. North Central Cooperative Oncology Group/National Cancer Institute; 1991.
46. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413.
47. SAS Institute Inc. SAS/STAT software: changes and enhancements through release 6.12. Cary, NC: SAS Institute, Inc.; 1997.
48. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958;53:457-481.
49. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257-263.
50. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
51. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-526.
52. Adelstein DJ. The community approach to salvage therapy for advanced head and neck cancer. Semin Oncol 1994;21(suppl 7):52-57.
53. Platinol AQ. PDR fifty-fifth edition physicians' desk reference. Montvale, NJ: Medical Economics Company, Inc.; 2001. p 1055-1057.
54. Lavertu P, Bonafede JP, Adelstein DJ, et al. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1998;124:401-406.
55. Wustrow TP, Wendt TG, Schalhorn A. Results of simultaneous radio-polychemotherapy in advanced inoperable cancer of the head and neck. Laryngol Rhinol Otol 1988; 67:567-575.
56. Matsuura S, Makino S, Satake B, et al. Autopsy findings in 255 cases of head and neck cancer. Gan To Kagaku Ryoho 1989;16:1954-1961.
57. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-883.
58. Regine WF, Valentino J, Sloan DA, et al. Postoperative radiation therapy for primary vs. recurrent squamous cell carcinoma of the head and neck: results of a comparative analysis. Head Neck 1999;21:554-559.
59. Davis RK, Perry DJ, Zajtchuk JT, et al: Induction chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 1983;91:627-631.
60. Suntharalingam M, Haas ML, Van Echo DA, et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 2001;91: 548-554.